期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

细胞增殖标志物Ki-67与乳腺癌 被引量：2

Cell proliferation marker Ki-67 and breast cancer
原文传递
导出
摘要 分子标志物在乳腺癌的治疗中已经得到了广泛应用，细胞增殖标志物Ki-67的表达与乳腺癌的临床病理特征及预后相关联，并且在评估新辅助化疗及内分泌治疗的疗效方面具有重要的预测价值。Ki-67高表达可作为乳腺癌的不良预后因素，其与肿瘤的发展、转移和预后高度相关。 Molecular markers have been widely used in the treatment of breast cancer. Cell proliferation markers Ki-67 antigen representing breast neoplasms proliferative activity is associated with clinic pathological features and prognosis and has an important predictive value in assessing the effect of neoadjuvant chemotherapy and endocrine therapy. High expression of Ki-67 is a bad prognostic factor of breast cancer, which is highly related to tumor progression, metastasis and prognosis.
作者 贾明 胡波飞 魏素菊
机构地区 河北医科大学第四医院肿瘤内科
出处 《国际肿瘤学杂志》 CAS 2011年第5期364-366,共3页 Journal of International Oncology
关键词 乳腺肿瘤 KI-67抗原 预后 Breast neoplasms Ki-67 antigen Prognosis
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献19

  • 1Cerdes J,Li L,Schlueter C,et al.Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67.Am J Pathol,138(4):867-873.
  • 2García-Velasco A,Mendiola C,Sánchez-Muoz A,et al.Prognostic value of hormonal receptors,p53,ki67 and HER2/neu expression in epithelial ovarian carcinoma,din Transl Oncol,2008,10(6):367-371.
  • 3Schindlbeck C,Hantschmann P,Zerzer M,et al.Prognostic impact of Ki67,p53,human epithelial growth factor receptor2,topoisomer-ase Ⅱ alpha,epidermal growth factor receptor,and nm23 expression of ovarian carcinomas and disseminated tumor cells in the bone marrow.Cancer,2007,17(5):1047-1055.
  • 4Li N,Zhang Y,Naylor MJ,et al.Betal integrins regulate mammary gland proliferation and maintain the integrity of mammary alveoli.EMBO J,2005,24(11):1942-1953.
  • 5Urruticoechea A,Smith I,Dowsett M.Proliferation marker Ki-67 in early breast cancer.J Clin Oncol,2005,23(28):7212-7220.
  • 6Koninki K,Tanner M,Auvinen A,et al.HER-2 positive breast cancer:decreasing proportion but stable inci-dence in Finnish population from 1982 to 2005.Breast Cancer Res,2009,11 (3):R37.
  • 7李宝江,朱志华,王军业,侯景辉,赵进明,张蓬原,姚广裕,王曦,龙浩,杨名添,戎铁.Ki67、P53、VEGF和C-erbB-2在乳腺癌组织中表达的相关性研究及其临床意义[J].癌症,2004,23(10):1176-1179. 被引量：126
  • 8Nishimura R,Osako T,Okumura Y,et al.Clinical significance of ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis.Br Cancer,2010,17(4):269-275.
  • 9Jung SY,Han W,Lee JW,et al.Ki-67 espression gives additional prognostic information on St.Callen 2007 and Adjuvant! Online risk categories in early breast cancer.Ann Surg Oncol,2009,16(5):1112-1121.
  • 10Guarneri V,Chavez-Mac M,Gregor L,et al.Use of Ki-67 in residual disease following preoperative chemotherapy to predict of recurrence and death in breast cancer patients.J Clin Oncol,2010,28 (15):621.

二级参考文献24

  • 1Gerdes J, Schwab U, Lemke H, et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation [J]. Iht J Cancer, 1983,31 (1):13-20.
  • 2Hall PA, Levison DA, Woods AL, et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms [J]. J Pathol, 1990, 162(4): 285-294.
  • 3Mullerat J, Deroide F, Winslet MC, et al. Proliferation and p53expression in anal cancer precursor lesions [J]. Anticancer Res,2003, 23 (3C): 2995-2999.
  • 4Liu M, Lawson G, Delos M, et al. Predictive value of the fraction of cancer cells immunolabeled for proliferating cell nuclear antigen or Ki67 in biopsies of head and neck carcinomas to identify lymph node metastasis: comparison with clinical and radiologic examinations [J]. Head Neck,2003,25(4): 280-288.
  • 5Tut VM, Braithwaite AL, Angus B, et al. Gyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53,wafl, pRb and Ki67 [J]. Br J Gancer,2001, 84(2): 270-275.
  • 6Bhatavdekar JM, Patel DD, Shah NG,et al. Prognostic significance of immunohisto-chemically localized biomarkers in stage Ⅱ and stage Ⅲ breast cancer: a multivariate analysis [J] . Ann Surg Oncol,2000, 7 (4): 305-311.
  • 7Vincent-Salomon A, Rousseau A, Jouve M, et al. Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy [J]. Eur J Cancer,2004(40): 1502-1508.
  • 8Nakopoulou L, Stefanaki K, Panayotopoulou E, et al. Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation [J]. Hum Pathol,2002,33(9): 863-870.
  • 9Norberg T, Klaar S, Kaff G, et al. Increased p53 nutation frequency during tumor progression-results from a breast cancer cohort [J]. Cancer Res, 2001, 61 (22): 8317-8321.
  • 10Davidoff AM, HerndonJE, Glover NS, et al. Relation between p53overoxpression and established prognostic factors in breast cancer [J]. Surgery, 1991, 110(2): 259-264.

共引文献137

同被引文献29

引证文献2

二级引证文献7

国际肿瘤学杂志
2011年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部